KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Kumquat Biosciences Inc.
- Study ID
- NCT07406633
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- GIST
- GIST - Gastrointestinal Stromal Tumor
- GIST Metastatic Cancer
- Gastro Intestinal Stromal Tumour
- Gastrointestinal Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KQB198 — DRUGOral KQB198
- Imatinib (Gleevec) — DRUGOral Imatinib
Study Details
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
Key Dates
- Start date
- May 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 46 participants (estimated)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: KQB198 in Combination with Imatinib
Primary Outcome Measure
Objective response rate (ORR) [ Time Frame: 30 months ]
Central Contacts
- Kumquat Clinical Development858-214-2700
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | - |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | - |
| Moffitt Cancer Center | Tampa | Florida | 33612 | - |
| University of Michigan Hospitals | Ann Arbor | Michigan | 48109 | - |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | - |
| Cleveland Clinic | Cleveland | Ohio | 44195 | - |
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98195 | - |
Find similar trials in Los Angeles, CA
Related Studies
- A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesPHASE1/PHASE2 · Recruiting · Deciphera Pharmaceuticals, LLC · Los Angeles, California
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsPHASE1 · Recruiting · ITM Solucin GmbH · Philadelphia, Pennsylvania
- Familial Investigations of Childhood Cancer PredispositionRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee